← Back to Clinical Trials
Recruiting NCT07242495

NCT07242495 Additional Effects of Immersive vr 360 Degree Videos With Aerobic Exercises on Cognitive Functions in Elderly With Mild Cognitive Impairment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07242495
Status Recruiting
Phase
Sponsor Foundation University Islamabad
Condition Cognitive Dysfunctions
Study Type INTERVENTIONAL
Enrollment 34 participants
Start Date 2024-09-14
Primary Completion 2025-12-10

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
VR 360 degree Videos and Aerobic Chair Exercises interventionChair Aerobic Exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 34 participants in total. It began in 2024-09-14 with a primary completion date of 2025-12-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

One of the key challenges faced by individuals with Mild Cognitive Impairment (MCI) is the decline in cognitive abilities, particularly global cognition, attention, and executive function, which are essential for maintaining independence and performing daily activities. Impaired cognition can significantly reduce quality of life in older adults, leading to difficulties in managing routine tasks, reduced social engagement, and increased dependency on caregivers. Common signs and symptoms include forgetfulness, difficulty concentrating, slower problem-solving, and challenges in planning or organizing daily activities. This study aims to explore and compare the effectiveness of two interventions-immersive Virtual Reality (VR) 360-degree videos combined with aerobic exercises, and aerobic exercises alone-in improving cognitive functions in older adults with MCI. Key outcome measures, including the Montreal Cognitive Assessment (MoCA) and Trail Making Test (TMT), will evaluate the effectiveness of the interventions on global cognition, attention, and executive function. We will include older adults aged 60 years and above with MoCA scores between 18-25 (MCI patients), who are able to perform independent ADLs. The participants will be assessed at the start of the intervention through the MoCA scale for MCI screening and baseline TMT testing for inclusion.

Eligibility Criteria

Inclusion Criteria: * Older population aged from 60years and above * Normal/ normal to corrected vision * MoCA Score of 18-25 for screening / MCI patients * Can do Independent ADLS Exclusion Criteria: * Individuals with preexisting conditions such as severe motion sickness that could be exacerbated by VR usage. * Communication impairments * Participants with other neurological disorders. * Sensory deficits (such as uncontrolled hearing or visual issues)

Contact & Investigator

Central Contact

Zara Amir, DPT

✉ sp24npt011@fui.edu.pk

📞 +92 3498273139

Frequently Asked Questions

Who can join the NCT07242495 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, studying Cognitive Dysfunctions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07242495 currently recruiting?

Yes, NCT07242495 is actively recruiting participants. Contact the research team at sp24npt011@fui.edu.pk for enrollment information.

Where is the NCT07242495 trial being conducted?

This trial is being conducted at Islamabad, Pakistan.

Who is sponsoring the NCT07242495 clinical trial?

NCT07242495 is sponsored by Foundation University Islamabad. The trial plans to enroll 34 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology